CA3221177A1 - Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases - Google Patents
Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases Download PDFInfo
- Publication number
- CA3221177A1 CA3221177A1 CA3221177A CA3221177A CA3221177A1 CA 3221177 A1 CA3221177 A1 CA 3221177A1 CA 3221177 A CA3221177 A CA 3221177A CA 3221177 A CA3221177 A CA 3221177A CA 3221177 A1 CA3221177 A1 CA 3221177A1
- Authority
- CA
- Canada
- Prior art keywords
- dihydro
- benzodioxin
- benzyl
- dioxino
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274222P | 2021-11-01 | 2021-11-01 | |
| US63/274,222 | 2021-11-01 | ||
| US202163293560P | 2021-12-23 | 2021-12-23 | |
| US63/293,560 | 2021-12-23 | ||
| US202263327496P | 2022-04-05 | 2022-04-05 | |
| US63/327,496 | 2022-04-05 | ||
| US202263342572P | 2022-05-16 | 2022-05-16 | |
| US63/342,572 | 2022-05-16 | ||
| PCT/US2022/048434 WO2023076679A1 (en) | 2021-11-01 | 2022-10-31 | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3221177A1 true CA3221177A1 (en) | 2023-05-04 |
Family
ID=86158674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3221177A Pending CA3221177A1 (en) | 2021-11-01 | 2022-10-31 | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11957671B2 (enExample) |
| EP (1) | EP4426284A4 (enExample) |
| JP (1) | JP2024542963A (enExample) |
| AU (1) | AU2022376563A1 (enExample) |
| CA (1) | CA3221177A1 (enExample) |
| WO (1) | WO2023076679A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11426399B2 (en) * | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6026099B2 (ja) | 1977-09-21 | 1985-06-21 | 財団法人微生物化学研究会 | ペプチド、その酸附加塩およびその製造法 |
| CA1182125A (en) | 1978-11-25 | 1985-02-05 | Hamao Umezawa | Process for producing threo-3-amino-2- hydroxybutanoyl-aminoacetic acids, as well as novel intermediates therefor and process for producing them |
| US4918092A (en) | 1983-12-21 | 1990-04-17 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
| US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
| DE4127849A1 (de) | 1991-08-22 | 1993-02-25 | Merck Patent Gmbh | Benzodioxanderivate |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| US5585492A (en) | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| DE19705450A1 (de) | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| DE19821003A1 (de) | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20030061825A (ko) | 2000-10-26 | 2003-07-22 | 화이자 프로덕츠 인크. | 피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
| WO2004029237A1 (en) | 2002-09-30 | 2004-04-08 | Bayer Healthcare Ag | Splice-variants of the human leukotriene a-4 hydrolase |
| US20060019269A1 (en) | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| NZ540148A (en) | 2002-12-20 | 2007-11-30 | Glaxo Group Ltd | Benzazepine derivatives for the treatment of neurological disorders |
| WO2005011736A1 (ja) | 2003-07-30 | 2005-02-10 | Tohoku Techno Arch Co., Ltd. | アルツハイマー病の予防および／または治療剤 |
| US20050272051A1 (en) | 2003-09-17 | 2005-12-08 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| CN101098866A (zh) | 2005-01-07 | 2008-01-02 | 辉瑞产品公司 | 杂芳族喹啉化合物及其作为pde10抑制剂的用途 |
| CN101189012A (zh) | 2005-03-31 | 2008-05-28 | 詹森药业有限公司 | 苯基和吡啶基lta4h调节剂 |
| JP4137081B2 (ja) | 2005-04-06 | 2008-08-20 | キヤノン株式会社 | 画像読取装置 |
| UA101943C2 (ru) | 2005-09-21 | 2013-05-27 | Декод Дженетикс Ехф | Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления |
| WO2007073405A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
| AU2006333522A1 (en) | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation |
| HUE031972T2 (en) | 2005-12-29 | 2017-08-28 | Celtaxsys Inc | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| CL2007003065A1 (es) | 2006-10-24 | 2008-01-25 | Wyeth Corp | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros |
| US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
| CN102946877B (zh) | 2010-03-18 | 2019-07-05 | 香港科技大学 | 乳突果及其分离的化合物在制备用于治疗神经疾病的药物中的用途 |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| CN103415513B (zh) | 2011-03-14 | 2016-01-20 | 勃林格殷格翰国际有限公司 | 白三烯产物的苯并二氧杂环己烷抑制剂 |
| EP2734516B1 (en) | 2011-07-19 | 2015-06-17 | Boehringer Ingelheim International GmbH | Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase |
| JP6080226B2 (ja) | 2012-03-06 | 2017-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン |
| WO2013134226A1 (en) * | 2012-03-06 | 2013-09-12 | Boehringer Ingelheim International Gmbh | Benzodioxanes for inhibiting leukotriene production |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2014014874A1 (en) | 2012-07-17 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Pyrazole derivatives which inhibit leukotriene production |
| CA2905340C (en) | 2013-03-12 | 2022-05-31 | Celtaxsys, Inc. | Low dose oral formulations of acebilustat |
| BR112015022864A8 (pt) | 2013-03-14 | 2019-11-26 | Celtaxsys Inc | composto, composição farmacêutica e uso dos mesmos |
| EP3022193B1 (en) | 2013-07-15 | 2017-04-26 | Boehringer Ingelheim International GmbH | Inhibitors of leukotriene production |
| JP2016523982A (ja) | 2013-07-15 | 2016-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成の阻害剤 |
| UA117498C2 (uk) | 2013-12-20 | 2018-08-10 | Новартіс Аг | Гетероарильні похідні бутанової кислоти як інгібітори lta4h |
| CN105891465A (zh) | 2014-11-11 | 2016-08-24 | 中南大学 | 一种诊断日本血吸虫循环抗原的方法 |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| EP3995141B1 (en) | 2016-04-28 | 2024-01-03 | Alkahest, Inc. | Plasma fractions as therapy for thymic cancer |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| BR112019003172A2 (pt) | 2016-08-18 | 2019-05-28 | Alkahest Inc | frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento |
| KR102399254B1 (ko) | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
| BR112019020798A2 (pt) | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
| AU2018257921B2 (en) | 2017-04-26 | 2024-06-06 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| KR20200067859A (ko) | 2017-10-13 | 2020-06-12 | 알카헤스트 인코포레이티드 | Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물 |
| US11426399B2 (en) * | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
-
2022
- 2022-10-31 US US17/977,687 patent/US11957671B2/en active Active
- 2022-10-31 WO PCT/US2022/048434 patent/WO2023076679A1/en not_active Ceased
- 2022-10-31 EP EP22888295.7A patent/EP4426284A4/en active Pending
- 2022-10-31 AU AU2022376563A patent/AU2022376563A1/en active Pending
- 2022-10-31 CA CA3221177A patent/CA3221177A1/en active Pending
- 2022-10-31 JP JP2024523819A patent/JP2024542963A/ja active Pending
-
2024
- 2024-02-23 US US18/585,939 patent/US12496296B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230146135A1 (en) | 2023-05-11 |
| WO2023076679A1 (en) | 2023-05-04 |
| US11957671B2 (en) | 2024-04-16 |
| AU2022376563A1 (en) | 2023-12-07 |
| JP2024542963A (ja) | 2024-11-19 |
| US12496296B2 (en) | 2025-12-16 |
| US20240252478A1 (en) | 2024-08-01 |
| EP4426284A4 (en) | 2025-11-12 |
| EP4426284A1 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11142529B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP7514534B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| EP3310785B1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US20180170941A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US20220226304A1 (en) | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | |
| CN115175911A (zh) | 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法 | |
| US12496296B2 (en) | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases | |
| US11505555B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| CN117729916A (zh) | 用于预防和治疗衰老相关疾病的白三烯a4水解酶（lta4h）的苯并二噁烷调节剂 | |
| HK40081455A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| EA039381B1 (ru) | Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения | |
| HK1254300B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK1254300A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |